Top Biotech Companies With Best Stability & Growth (3,585)
.png)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products.
GRAIL's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is rising, with 2025 total revenue reaching roughly $147M and U.S. Galleri revenue about $136–137M. Early 2026 momentum continued as Galleri revenue increased to $39.8M on sharply higher test volumes (over 56,000 in Q1).
Strategic Partnerships: Distribution and access are expanding through integrations with Quest Diagnostics and Epic’s EHR that streamline ordering and broaden provider access. Additional channels such as Priority Health’s employer offering indicate widening availability.
Investor Backing & Capital Strength: Capital resources are sizable, including $823.1M in cash and securities as of March 31, 2026 and a $110M equity investment from Samsung entities. Management indicates a multiyear runway into 2030, supporting continued trials and commercialization.
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the...
Benchling's Top Stability & Growth Strengths
Strong Revenue Growth: ARR is estimated to have surpassed $200M by May 2024 with roughly 27% year over year growth, indicating ongoing top-line expansion. While slower than pre-2022 hypergrowth, this still reflects material scaling at enterprise revenue levels.
Market Expansion: The company reports welcoming 240 new customers in 2024 and now powers over 1,300 biotechnology companies. This evidences continued penetration and up-market traction in life-sciences R&D.
Product Line Growth: New modules and AI capabilities launched in 2024, including Benchling Bioprocess and analytics features, broadened the platform beyond research into development and data analysis. The PipeBio acquisition further strengthened high-throughput biologics and AI-assisted discovery.
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform...
SOPHiA GENETICS's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is accelerating, with FY2025 up 19% and Q1 2026 up 22%, and guidance of $92–$94M implies about 20–22% further growth in 2026. Record analysis volumes and rising net dollar retention support the trajectory.
Strategic Partnerships: High-profile collaborations with Memorial Sloan Kettering (MSK‑ACCESS and MSK‑IMPACT), AstraZeneca, MD Anderson, and large U.S. health systems expand access and credibility for new applications. These relationships are highlighted as drivers of continued double-digit growth through 2026.
Market Expansion: The company is adding customers and scaling usage globally—reaching 537 core genomics customers and a record 108,000 analyses in Q1 2026—with particularly strong momentum in the U.S. and APAC. Reaffirmed U.S. expansion and new application launches are expected to sustain this momentum.
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Click Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Fresh capital arrived via a $50M April 2026 investment from Boehringer Ingelheim alongside an earlier Series C led by Dassault Systèmes/Medidata, extending resources for commercialization. The concurrent transfer of CT‑155 commercialization/marketing rights signals committed funding tied to revenue‑bearing activities.
Strategic Partnerships: Long‑running collaborations deepened with Boehringer Ingelheim (commercialization rights for CT‑155) and Otsuka (Rejoyn), while Dassault Systèmes/Medidata broadened a technology partnership to support scale‑up. A January 2026 partnership with Ultrahuman expands reach beyond traditional PDT channels.
Product Line Growth: Recent FDA authorizations for CT‑132 (episodic migraine) and Rejoyn (MDD) broaden the platform and advance the company toward launches. These milestones are highlighted as bolstering credibility for future products.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Launched and acquired products are scaling, with oncology assets from the Seagen deal and brands such as Padcev, oncology biosimilars, Nurtec, Lorbrena, Abrysvo, Eliquis, and the Vyndaqel family cited as key contributors. Early‑2026 updates describe a meaningful uptick from these newer and in‑line medicines.
Innovation-Driven Growth: Management highlights a robust late‑stage pipeline with numerous pivotal study starts planned in 2026 and catalysts across oncology, vaccines, and metabolic disease. Programs such as an ADC (sigvotatug vedotin) and a GLP‑1 RA (berobenatide) are positioned to convert into future approvals and launches.
Diversified Revenue Streams: Growth beneath the surface is coming from multiple non‑COVID franchises rather than a single product, spanning oncology (including Seagen’s ADCs), vaccines, neurology, and cardiovascular. This breadth is helping to offset normalization in COVID‑related sales.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health's Top Stability & Growth Strengths
Product Line Growth: Multiple 2026 launches and updates, including Flatiron Telescope, AI‑extracted real‑world progression, a new AI data‑quality framework, and harmonized multinational datasets, signal an expanding offering. A strong 2026 scientific presence (e.g., ASCO/ISPOR) showcases next‑generation capabilities aligned to growing use cases.
Market Expansion: International build‑out is evident in first AI‑powered prostate cancer datasets for the UK and Germany and new collaborations across the UK and Europe. Company materials also highlight a markedly larger multinational network spanning the UK, Germany, and Japan.
Strategic Partnerships: Collaborations with Unicancer for regulatory‑grade evidence and point‑of‑care integrations with Abbott and Quest indicate deepening enterprise engagement. Participation in ecosystem programs and multi‑year collaborations suggests a partner‑led growth approach.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and...
Inato's Top Stability & Growth Strengths
Innovation-Driven Growth: AI site selection and AI patient pre-screening launched in 2025–2026 are described as streamlining screening and improving enrollment efficiency. These releases signal a deepening product footprint aligned to faster activation and more representative enrollment.
Strategic Partnerships: A 2025 data partnership with RealTime eClinical Solutions and highlighted work with major pharma logos are presented as ecosystem validation and traction. These collaborations integrate site performance data and extend marketplace reach.
Market Expansion: The network is portrayed as growing from about 5,500 to 6,000+ research sites across 50+ countries into 2026. Sponsor materials and industry posts indicate steady expansion of marketplace breadth.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raised is described as substantial, with a $372M Series D in June 2024 led by a16z and participation from Sanofi, explicitly earmarked to grow the pipeline and AI platform. References to $600M+ in total funding and ongoing hiring point to a reinforced capital base supporting expansion.
Strategic Partnerships: Collaborations with Sanofi and OpenAI are presented as first-in-class efforts to apply AI across drug development, signaling external validation and increased resourcing. A 2025 Sanofi licensing deal worth up to €545M further indicates the capability to progress and transact assets with blue‑chip partners.
Product Line Growth: Pipeline activity is shown to be broadening via in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor in Dec 2025) and movement into the clinic, including first‑in‑human dosing on June 9, 2026. Together, these moves suggest more programs are entering and advancing through clinical stages.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Total revenue grew 23% year over year to $255.9M in 2025, with software up 10.6% and drug discovery more than doubling to $56.4M. Guidance for 2026 points to 10–15% software ACV growth, and Q1 2026 ACV rose 12% year over year.
Strategic Partnerships: Royalty‑eligible collaborative programs increased to 16 by year‑end 2025, with multiple partner milestones (e.g., Takeda’s TYK2 from Nimbus, Structure Therapeutics updates) and integrations like Lilly’s TuneLab in LiveDesign signaling ecosystem momentum. These relationships can generate milestones and potential royalties that support future growth.
Investor Backing & Capital Strength: Cash and marketable securities were about $402M at year‑end 2025 (approximately $406M at Q1 2026), and operating expenses are guided below 2025 levels for 2026. This liquidity and cost discipline provide runway to advance the hosted transition and the discovery portfolio.
We bring together one of the world’s largest libraries of multimodal clinical and molecular data with a robust suite of AI tools to help physicians personalize care in real time, connect patients with therapies and clinical trials, and enable partners to accelerate discovery and development of new treatments. With ~8 million de-identified research records and 350+ petabytes of data, Tempus partners...
Tempus AI's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is reported at about $1.27B for 2025 (~80–83% YoY), with Q4 2025 at $367.2M (+83% YoY) and Q1 2026 at $348.1M (+36% YoY); full‑year 2026 is guided to $1.59–$1.60B (~25% growth). Segment data show Diagnostics up 34.7% and Data & Applications up 40.5% YoY in Q1 2026.
Strategic Partnerships: Record total contract value exceeding $1.1B and multi‑year collaborations with AstraZeneca, Merck, Gilead, and Bristol Myers Squibb are highlighted. These arrangements support growth in data/software lines and add forward revenue visibility.
Product Line Growth: MRD testing reached ~6,500 in Q1 2026 (up ~500% YoY), and acquisitions of Ambry Genetics, Paige.AI, and Deep 6 AI broaden testing and AI capabilities. Management points to horizontal integration and cross‑selling (e.g., with Ambry) as contributors to expected growth.
Caristo Diagnostics has been formed to bring revolutionary cardiovascular diagnostic tools to patients worldwide. Our proprietary technology transforms the accuracy of routine cardiac CT scans by extracting new information that is otherwise invisible, greatly enhancing the power to predict cardiovascular risk and refine treatment decisions. Our Website: https://www.caristo.com Follow us on Twitter: https://twitter.com/CaristoHeart
Shellworks is a design-led techbio company that creates uncompromising, compostable packaging solutions made from naturally-derived materials, offering a sustainable alternative to conventional plastics.
Hamilton Company is a global enterprise with headquarters in Reno, Nevada; Franklin, Massachusetts; and Bonaduz, Switzerland and subsidiary offices throughout the world. We are an industry leader in the design and manufacture of liquid handling, process analytics, robotics and automated storage solutions. For more than 60 years, Hamilton has been meeting customer needs with a combination of quality materials and skilled...
Gator Bio is a Silicon Valley biotech company with a mission to help biopharma scientists gain research insights faster. We fused engineering and science expertise to create novel analytical technologies that achieve better performance and more convenient solutions at a fraction of the cost of existing products. This is the biolayer interferometry solution you've been waiting for.
Every second of every hour of every day, 44 of our products are employed in the battle against cancer. Customers put their trust in Epredia over a billion times every year. Epredia was established in July 2019 through an acquisition by PHC Group from Thermo Fisher Scientific. Powered by trusted brands such as Shandon, Microm, Menzel Gläser and Richard-Allan Scientific,...
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Our lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). We are also advancing an early-stage portfolio...
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company dedicated to discovering and developing innovative, novel precision cancer medicines for underserved patients. The company focuses on targeting key drivers of cancer cell growth and resistance, with a pipeline that includes JAK2V617F and KAT6A programs and degrader antibody conjugates to treat various cancers, including breast cancer and myeloproliferative neoplasms.
Enviromedica is an innovative natural health and wellness company that applies science-based evolutionary theory to create foundational support products. They focus on ancestral health, microbiome support, and rewilding the gut.
theMednet is the premier peer-to-peer digital platform helping physicians unlock expert knowledge. Our mission is to facilitate knowledge and information sharing between physicians and help address disparities in patient care. theMednet is a physician-only network to access invaluable expert advice and request answers to real world clinical questions. All content serves as a resource for physicians to access expert knowledge, contribute...
The Quality Consulting Group is a pharmaceutical, biotechnology, food and medical device specialty consultant that supports the manufacturing industry; services are provided in multiple areas including: Regulatory Compliance, Quality Operations, Validation, Manufacturing, Training and Technical Support. Starting, as individual services provider since 2002, Quality Consulting Group has supported clients implementing the latest standards such as Validation Guidance, ICH Guidelines, and...
